肝癌放疗前后白介素2受体水平变化的意义

Significance of interleukin-2 receptor in hepatocellular carcinoma after radiotherapy

目的探讨肝癌患者放疗前后白介素2受体(IL-2R)水平与临床治疗效果之间的关系。方法用ELISA试剂盒法检测50例非手术肝癌患者开始放疗的前1d、放疗开始后1周、放疗开始后3周血液中白介素2受体的水平。根据近期放疗治疗效果分为有效组和无效组,比较治疗前后白介素2受体的变化。结果有效组放疗前1d、放疗后1周及3周IL-2R水平差异有统计学意义(P<0.05),而无效组差异无统计学意义(P>0.05)。放疗前1d和放疗后1周两组间血清白介素2受体水平比较,差异无统计学意义(P>0.05),而放疗后3周两组间IL-2R水平比较差异有统计学意义(P<0.05)。结论肝癌患者放疗前后血浆IL-2R的水平对于肝癌患者治疗效果的监测和预后有着重要的指导作用。

Objective To investigate the relationship between the interleukin 2 receptor level and clinical treatment effect of patients with liver cancer before and after radiotherapy. Methods Interleukin-2 receptor level of 50 cases with liver cancer was detected by ELISA method about one day before radiotherapy, one week after radiotherapy, three weeks after radiotherapy. 50 cases were divided into effective group and invalid group according to recent radiotherapy treatment and the interleukin-2 receptor changes was compared before and after treatment. Results There was significant difference about interleukin-2 receptor level among the day before radiotherapy, one week and three weeks after radiotherapy in the effective group （P 0.05）, while there was no significant difference in the ineffective group （P 0.05）. There was no significant difference between two groups 1 day before and 1 week after radiotherapy （P 0.05）, and there was statistically significant between the two groups three weeks after radiotherapy （P 0.05）. Conclusion The plasma IL-2R levels in patients with hepatocellular carcinoma before and after radiotherapy has guiding role for monitoring the effect of the treatment and prognosis.